ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) Momentum Rank : 0 (As of Dec. 13, 2024)

View and export this data going back to 2016. Start your Free Trial

What is ExpreS2ion Biotech Holding AB Momentum Rank?

ExpreS2ion Biotech Holding AB has the Momentum Rank of 0.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

ExpreS2ion Biotech Holding AB Momentum Rank Related Terms

Thank you for viewing the detailed overview of ExpreS2ion Biotech Holding AB's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

ExpreS2ion Biotech Holding AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) » Definitions » Momentum Rank

Comparable Companies

Traded in Other Exchanges

5JD0:Germany

Address

c/o Mindpark, Ronnowsgatan 8c, Helsingborg, SWE, S-252 25

Website

https://www.expres2ionbio.com

ExpreS2ion Biotech Holding AB has developed a technology platform, ExpreS2, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS2 is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. The company has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with research institutions and companies.

ExpreS2ion Biotech Holding AB Headlines

No Headlines